(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease ...

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

Yesterday saw a new campaign group call for the UK government to override the patent on Roche's breast cancer drug Kadcyla if the ... ongoing Accelerated Access Review can help join up the UK's ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

A study involving an experimental cancer drug being developed by Roche Holding (RHHBY, ROG.VX) showed it delayed disease progression in women with a specific type of breast cancer compared to ...

ZURICH (Dow Jones)--Roche Holding AG (ROG.VX) Friday reported positive results from a late-stage study that compared its experimental breast cancer drug trastuzumab emtansine to a rival product ...